All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Serina Therapeutics Q3 net loss widens on higher R&D costs

By Reuters News


Overview

  • US biotechnology firm's Q3 revenue rose to $125,000 from zero a year ago

  • Net loss widened to $7.9 mln from $4.7 mln on higher R&D and G&A expenses

  • Company advanced SER-252 Parkinson's study to Cohort 2 after positive safety review


Outlook

  • Serina expects topline single-ascending-dose data for SER-252 in 1H 2027

  • Company continues dosing in Cohort 2 of SER-252 Parkinson's disease study

  • Serina says additional clinical data will further characterize SER-252's safety and efficacy profile


Result Drivers

  • CLINICAL TRIAL PROGRESS - Advancement of SER-252 Parkinson's study to Cohort 2 after independent safety review and initiation of higher-dose testing

  • INCREASED R&D SPEND - Higher research and development expenses driven by clinical-related activities, contract manufacturing, and compensation

  • EARLY CLINICAL OBSERVATIONS - Initial blinded observations from Cohort 1 showed pharmacokinetic findings consistent with intended prolonged drug exposure and some improvement in motor function in individual patients


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$125,000

$0 (2 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Serina Therapeutics, Inc. is $9.50, about 573.8% above its November 12 closing price of $1.41


Reuters Recommended Reads

  • Nov 12 - Relmada Therapeutics Q3 net loss widens on higher R&D costs

  • Nov 12 - SELLAS Life Sciences Q3 net loss widens on higher R&D costs

  • Nov 12 - Taysha Gene Therapies Q3 net loss widens on higher R&D costs


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.